Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry.So far this year, Eli Lilly (LLY 0.54%) has been on an absolute tear and is swiftly becoming the world's most prolific pharmaceutical operation in my eyes. In addition to the unprecedented growth of its diabetes and obesity care treatments, Lilly has also secured some major wins from the Food and Drug Administration (FDA), including approval for both its Alzheimer's disease candidate and eczema drug.While it looks ...

Results to be Featured in Oral Late Breaker PresentationSAN DIEGO, Nov. 12, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that results from the company's Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH; also ...

Viking stock has slipped more than 20% from its peak.Viking Therapeutics (VKTX -0.54%) soared to center stage earlier this year as a potentially promising player in one of today's highest-growth healthcare markets: weight loss drugs. The biotech company presented solid data for a candidate that could eventually rival blockbuster weight loss drugs from big pharma companies Eli Lilly and Novo Nordisk. And in just one trading session, the shares skyrocketed, rising more than 100%.Since then, Viking has reitera ...

All signs are pointing toward its continued success.When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the stock will go up." And while that proposition is certainly true with Viking Therapeutics, (VKTX 4.52%) there's more than one reason for why the stock is worth buying.In fact, there are at least four arguments supporting an investment, so let's take a look at each.1. It's racing closer to generating revenue for the first timeViking i ...

The company's latest presentation supports the idea that its lead program will make billions.With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (VKTX 1.44%) are a hot commodity, to say the least. And as of early November, there's one more big green flag suggesting that investors who take the plunge will be wealthier than before. Even an investment on the scale of $5,000 could see a meaningful run-up, assuming its plans to compete in the market for anti-obesity medicines com ...

The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales.Shares of Viking Therapeutics (VKTX -13.36%) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the company showed the medical community and investors results that suggest its experimental anti-obesity tablet, tentatively named VK2735, could go on to generate blockbuster sales.Viking's previous positive results for the experimental treatments in its pipeline haven't gon ...

Are we ready for the Great Obesity Drug Gold Rush of the 2020s?For high-profile biotech Viking Therapeutics (VKTX -13.36%), Monday was very much a good news/bad news kind of day. The company reported quite encouraging clinical results from a version of its investigational weight-loss drug. Before long, however, this was overshadowed by promising news from rival developers of similar treatments.Ultimately, after an early surge, Viking's shares closed the day more than 13% lower in price.Weight loss for profi ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum.He leads the investing group Growth Stock Forum which features: a model ...

Viking Therapeutics (VKTX) stock jumped 6% out of the gate Monday, but was last seen notably lower. The volatility comes after the biopharmaceutical company reported positive new clinical data for its weight-loss pill, VK2735.The data released by Viking showed that adults taking the highest dosage of the oral VK2735 tablet lost an average of 8.2% of their body weight in just four weeks, or 6.8% more than those that received a placebo."We believe the VENTURE data demonstrate VK2735's promising efficacy and t ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...